First commercial sale of Zerviate in China

6 December 2024

French ophthalmics specialist Nicox (Euronext Growth Paris: FR0013018124) has announced the first commercial sale of Zerviate (cetirizine ophthalmic solution) in China by its exclusive Chinese partner OcuMension Therapeutics (HKG: 477).

Zerviate is indicated for ocular itching associated with allergic conjunctivitis and was approved in China in September 2024.

Nicox pointed out that Zerviate is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in Zyrtec, and is currently commercialized in the USA for ocular itching associated with allergic conjunctivitis by Nicox’ exclusive US partner, Harrow Inc.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK